BioPharmSignal logoBioPharmSignal

Biotech News

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences

PMV Pharmaceuticals (PMVP)PMV PharmaceuticalsCompany update

PRINCETON, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H.

Related news

PMVPPMV Pharmaceuticals2026-08-14 12:00 EST

PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights

MMSIMerit Medical2026-08-05 16:00 EST

Merit Medical to Participate in Upcoming Investors Conferences in August

FATEFate Therapeutics2026-07-01 20:05 EST

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences

ZNTLZentalis2026-08-17 20:01 EST

Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

ZNTLZentalis2026-08-14 02:23 EST

Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering

MGNXMacroGenics2026-07-02 13:25 EST

MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals

ENTAEnanta Pharmaceuticals2026-06-18 11:00 EST

Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)

REGNRegeneron Pharmaceuticals2026-08-19 20:05 EST

Regeneron Announces Investor Conference Presentations

IMTXImmatics2026-07-17 14:25 EST

Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026

ENTAEnanta Pharmaceuticals2026-06-23 09:10 EST

Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus

View all latest news

PMV Pharmaceuticals

Mutant-p53 Precision Oncology PMV Pharmaceuticals develops small-molecule precision therapies that target specific mutations in the p53 tumor-suppressor protein. Its platform is designed to restore the normal cancer-suppressing function of structurally altered p53 proteins, addressing mutations found across multiple solid-tumor...

Recent company news

PMVPPMV Pharmaceuticals2026-08-14 12:00 EST

PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights

PMVPPMV Pharmaceuticals2026-05-12 12:00 EST

PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights

PMVPPMV Pharmaceuticals2026-04-22 12:00 EST

PMV Pharmaceuticals Announces Board Chair Transition

PMVPPMV Pharmaceuticals2026-03-06 13:00 EST

PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights

PMVPPMV Pharmaceuticals2026-02-26 13:00 EST

New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors

Stock data

Close
1.33 USD
Market cap
62.93M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States